John Stefan, Eckardt Kai-Uwe
Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany.
Chest. 2007 Oct;132(4):1379-88. doi: 10.1378/chest.07-0167.
Acute renal failure (ARF) with the concomitant need for renal replacement therapy (RRT) is a common complication of critical care medicine that is still associated with high mortality. Different RRT strategies, like intermittent hemodialysis, continuous venovenous hemofiltration, or hybrid forms that combine the advantages of both techniques, are available and will be discussed in this article. Since a general survival benefit has not been demonstrated for either method, it is the task of the nephrologist or intensivist to choose the RRT strategy that is most advantageous for each individual patient. The underlying disease, its severity and stage, the etiology of ARF, the clinical and hemodynamic status of the patient, the resources available, and the different costs of therapy may all influence the choice of the RRT strategy. ARF, with its risk of uremic complications, represents an independent risk factor for outcome in critically ill patients. In addition, the early initiation of RRT with adequate doses is associated with improved survival. Therefore, the "undertreatment" of ARF should be avoided, and higher RRT doses than those in patients with chronic renal insufficiency, independent of whether convective or diffusive methods are used, are indicated in critically ill patients. However, clear guidelines on the dose of RRT and the timing of initiation are still lacking. In particular, it remains unclear whether hemodynamically unstable patients with septic shock benefit from early RRT initiation and the use of increased RRT doses, and whether RRT can lead to a clinically relevant removal of inflammatory mediators.
急性肾衰竭(ARF)且同时需要肾脏替代治疗(RRT)是重症医学中常见的并发症,其死亡率仍然很高。有不同的RRT策略,如间歇性血液透析、连续性静脉-静脉血液滤过或结合了两种技术优点的混合形式,本文将对此进行讨论。由于尚未证明哪种方法具有总体生存获益,因此选择对每个患者最有利的RRT策略是肾病学家或重症监护医生的任务。基础疾病、其严重程度和阶段、ARF的病因、患者的临床和血流动力学状态、可用资源以及不同的治疗费用都可能影响RRT策略的选择。ARF因其存在尿毒症并发症的风险,代表了重症患者预后的独立危险因素。此外,早期以适当剂量启动RRT与生存率提高相关。因此,应避免对ARF的“治疗不足”,对于重症患者,无论采用对流还是扩散方法,都应给予比慢性肾功能不全患者更高的RRT剂量。然而,关于RRT剂量和启动时机仍缺乏明确的指南。特别是,血流动力学不稳定的感染性休克患者是否能从早期启动RRT和使用增加的RRT剂量中获益,以及RRT是否能导致临床上相关的炎症介质清除仍不清楚。